Skip to main content
Explore URMC
menu

Brea C. Lipe, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 276-2596

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

I am the clinical director of Wilmot's multiple myeloma program, and in the laboratory and in the clinic, I am focused on improving the care of patients with multiple myeloma and other plasma cell dyscrasias. Treatment options and our understanding of multiple myeloma have changed dramatically in the last 10 years. The rapid pace of change, intrinsic disease complexity, and the ability to impact patient lives still leaves me amazed and humbled every day.

I believe that it's important to know my patients as individuals to understand the situational circumstance and personality that drives their treatment goals. Multiple myeloma is a lifelong journey and a strong partnership with my patients is essential to achieving the best quality of care. I have a strong interest in clinical research and like to offer my patients a variety of clinical trial options and treatments based on the most recent data. I have a dedicated support team, so that we can offer patients a team with real myeloma-specific expertise.

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Outside of work, I love to grow things -- flowers, vegetables, orchids, animals, children. I have gotten some of my best gardening tips from my patients.

Conditions I treat:

- Multiple myeloma
- Other plasma cell disorders

Research

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Credentials

Education

2005
MD | Albany Medical Center Hospital

Post-doctoral Training & Residency

07/01/2008 - 06/30/2011
Fellowship in Hematology & Oncology at Dartmouth-Hitchcock Medical Center

07/01/2006 - 06/30/2008
Residency in Internal Medicine at Dartmouth-Hitchcock Medical Center

07/01/2005 - 06/30/2006
Internship in Internal Medicine at Dartmouth-Hitchcock Medical Center

VIEW ALL expand_more

Awards

2017 - Present
Leadership Academy
Sponsor: Southwest Oncology Group (SWOG)

2011
Department of Internal Medicine OSARM Faculty Incubator Scholar

2011
Clinical Research Training Institute Clinical Scholar for ASH

2009
Award for Excellence in Teaching

2007
Award for Excellence in Teaching

2001 - 2005
Frank C. Knievel Scholarship Award

1996 - 2001
First Generation Diversity Scholarship

VIEW ALL expand_more

Publications

Journal Articles

8/4/2021
Keren DF, Bocsi G, Billman BL, Etzell J, Faix JD, Kumar S, Lipe B, McCudden C, Montgomery R, Murray DL, Rai AJ, Redondo TC, Souter L, Ventura CB, Ansari MQ. "Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology." Archives of pathology & laboratory medicine.. 2021 Aug 4; Epub 2021 Aug 04.

11/2020
Lipe, B. "Multiple Myeloma Insights: Older Adults With Multiple Myeloma: Q&A on Care Management" . Medpage Today. 2020; .

11/2020
Gasparetto, C; Lentzsch, S; Schiller, G; Callander, N; Tuchman, S; Chen, C; White, D; Kotb, R; Sutherland, H; Sebag, M; Baljevic, M; Bensinger, W; LeBlanc, R; Venner, C; Bahlis, N; Rossi, A; Biran, N; Sheehan, H; Saint-Martin, J; Van Domelen, D; Kai, K; Shah, J; Shacham, S; Kauffman, M; Lipe, B. "Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma" . eJHaem. 2020; .

VIEW ALL PUBLICATIONS